JP2010510241A5 - - Google Patents

Download PDF

Info

Publication number
JP2010510241A5
JP2010510241A5 JP2009537388A JP2009537388A JP2010510241A5 JP 2010510241 A5 JP2010510241 A5 JP 2010510241A5 JP 2009537388 A JP2009537388 A JP 2009537388A JP 2009537388 A JP2009537388 A JP 2009537388A JP 2010510241 A5 JP2010510241 A5 JP 2010510241A5
Authority
JP
Japan
Prior art keywords
formulation
topiramate
release
component
maxir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009537388A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010510241A (ja
JP5489719B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/084961 external-priority patent/WO2008061226A2/en
Publication of JP2010510241A publication Critical patent/JP2010510241A/ja
Publication of JP2010510241A5 publication Critical patent/JP2010510241A5/ja
Application granted granted Critical
Publication of JP5489719B2 publication Critical patent/JP5489719B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009537388A 2006-11-17 2007-11-16 トピラマートの徐放性配合物 Expired - Fee Related JP5489719B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85950206P 2006-11-17 2006-11-17
US60/859,502 2006-11-17
PCT/US2007/084961 WO2008061226A2 (en) 2006-11-17 2007-11-16 Sustained-release formulations of topiramate

Publications (3)

Publication Number Publication Date
JP2010510241A JP2010510241A (ja) 2010-04-02
JP2010510241A5 true JP2010510241A5 (enExample) 2010-08-26
JP5489719B2 JP5489719B2 (ja) 2014-05-14

Family

ID=39400596

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009537388A Expired - Fee Related JP5489719B2 (ja) 2006-11-17 2007-11-16 トピラマートの徐放性配合物

Country Status (9)

Country Link
US (10) US8298576B2 (enExample)
EP (2) EP2394643B1 (enExample)
JP (1) JP5489719B2 (enExample)
AU (1) AU2007319141B2 (enExample)
CA (1) CA2618240C (enExample)
DE (1) DE07870164T1 (enExample)
ES (2) ES2555066T3 (enExample)
MX (1) MX2009001711A (enExample)
WO (1) WO2008061226A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US9744137B2 (en) * 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
EP2394643B1 (en) 2006-11-17 2015-09-02 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
CN102114002B (zh) * 2006-12-04 2016-05-11 苏佩努斯制药公司 托吡酯的增强的立即释放制剂
JP5424571B2 (ja) * 2007-04-12 2014-02-26 協和発酵キリン株式会社 トピラマート含有固形製剤
US20090304789A1 (en) 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
EP2341912B1 (en) 2008-09-05 2014-01-22 Supernus Pharmaceuticals, Inc. Method of treatment of attention deficit/hyperactivity disorder (adhd)
EP2403487A2 (en) 2009-03-04 2012-01-11 Fdc Limited Oral controlled release dosage forms for water soluble drugs
JP5827952B2 (ja) * 2009-10-09 2015-12-02 ユンジン・ファーム・カンパニー・リミテッドYungjin Pharm. Co. Ltd. 速効性と持続性を同時に有する薬剤学的組成物
CN107080846A (zh) 2010-07-09 2017-08-22 詹姆斯.特林卡.格林 用于包括瑞格列净的短半衰期药物的组合立即/延迟释放递送系统
EP3485878A1 (en) 2010-09-01 2019-05-22 Arena Pharmaceuticals, Inc. Modified-release dosage forms of 5-ht2c agonists useful for weight management
US20120135104A1 (en) * 2010-11-30 2012-05-31 Bhiku Patel Enhanced Absorption of Omega Fatty Acid Oils
AU2013217013B2 (en) 2012-02-08 2017-04-20 Supernus Pharmaceuticals, Inc. Modified release formulations of viloxazine
CN102579367B (zh) * 2012-03-23 2014-03-12 中国人民解放军军事医学科学院毒物药物研究所 托吡酯缓释药物组合物、其制备方法及用途
CN103316026B (zh) 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 含芬特明和托吡酯的联合产品及其制备方法
JP6055076B2 (ja) 2012-03-23 2016-12-27 インスティテュート オブ ファーマコロジー アンド トキシコロジー アカデミー オブ ミリタリー メディカル サイエンシズ ピー.エル.エー.チャイナ シネフリン及びトピラマートを含む組み合わせ製品
IN2014DN07797A (enExample) * 2012-03-29 2015-05-15 Daicel Corp
KR101446066B1 (ko) 2012-12-14 2014-10-01 박재돈 구안파신 함유 경구용 서방성 캡슐제 조성물
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2014167439A1 (en) * 2013-03-26 2014-10-16 Wockhardt Limited Modified release pharmaceutical compositions of topiramate or salts thereof
IN2013MU01868A (enExample) * 2013-05-27 2015-06-26 Cadila Healthcare Ltd
FR3007651A1 (fr) * 2013-06-27 2015-01-02 Assist Publ Hopitaux De Paris Composition pharmaceutique sous forme de granules pour le traitement de desordres metaboliques chez l'enfant
US10278948B1 (en) 2015-09-03 2019-05-07 Tian Xia Method for transnasal delivery of anticonvulsant and therapeutic treatments
US20170348235A1 (en) * 2015-09-16 2017-12-07 Corr-Jensen, Inc. Multi-phase release of sports nutrition and energy drink compositions utilizing lipid particulates
WO2017048859A1 (en) * 2015-09-16 2017-03-23 Corr-Jensen, Inc. Multi-phase release of sports nutrition and energy drink compositions utilizing lipid particulates
CN105326814A (zh) * 2015-10-09 2016-02-17 北京万全德众医药生物技术有限公司 托吡酯缓释制剂药物组合物
CN107308119B (zh) * 2017-07-10 2019-12-17 浙江万方生物科技有限公司 一种高水溶性酒石酸泰万菌素颗粒及其制备方法
JP7005229B2 (ja) * 2017-08-24 2022-01-21 キヤノン株式会社 記録装置、及び記録装置の制御方法
KR20200045496A (ko) 2017-08-29 2020-05-04 콘리그 파마 에이피에스 수플라타스트 토실레이트를 포함하는 조성물
US20210000867A1 (en) * 2019-06-19 2021-01-07 Glycan Industries LLC New route and engineering protocols for alzheimers disease prevention, treatment and neuronal rebuilding
CN110638791A (zh) * 2019-10-31 2020-01-03 浙江普利药业有限公司 托吡酯缓释胶囊及其制备方法
US20240009181A1 (en) * 2022-07-08 2024-01-11 Jason Eric Schiffman Method for the treatment and prophylaxis of substance-related and/or addictive disorders including substance/medication-induced depressive disorders, bipolar and related disorders, and anxiety disorders and compositions useful for the same
GB2643925A (en) 2024-09-09 2026-03-11 Novumgen Ltd An orodispersible tablet of topiramate and its process of preparation
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2528378A (en) 1947-09-20 1950-10-31 John J Mccabe Jr Metal salts of substituted quaternary hydroxy cycloimidinic acid metal alcoholates and process for preparation of same
NL272723A (enExample) * 1951-05-31
US2675619A (en) * 1952-05-31 1954-04-20 Mcbee Co Drafting instrument
US2738303A (en) 1952-07-18 1956-03-13 Smith Kline French Lab Sympathomimetic preparation
US2996431A (en) * 1953-12-16 1961-08-15 Barry Richard Henry Friable tablet and process for manufacturing same
US2781354A (en) * 1956-03-26 1957-02-12 John J Mccabe Jr Imidazoline derivatives and process
US3036118A (en) * 1957-09-11 1962-05-22 Wyandotte Chemicals Corp Mixtures of novel conjugated polyoxyethylene-polyoxypropylene compounds
US2979578A (en) * 1958-10-30 1961-04-11 Litton Systems Inc Omnipositional rotary switch
US3139383A (en) * 1961-06-26 1964-06-30 Norton Co Encapsulated time release pellets and method for encapsulating the same
NL130291C (enExample) 1964-01-02
US3829506A (en) * 1971-06-01 1974-08-13 Basf Wyandotte Corp Biodegradable surface active agents having good foam properties and foam stabilizing characteristics
US3962414A (en) * 1972-04-27 1976-06-08 Alza Corporation Structured bioerodible drug delivery device
US3811444A (en) * 1972-12-27 1974-05-21 Alza Corp Bioerodible ocular device
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
US3992518A (en) 1974-10-24 1976-11-16 G. D. Searle & Co. Method for making a microsealed delivery device
US4093709A (en) * 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4079038A (en) * 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
US4066747A (en) * 1976-04-08 1978-01-03 Alza Corporation Polymeric orthoesters housing beneficial drug for controlled release therefrom
US4070347A (en) * 1976-08-16 1978-01-24 Alza Corporation Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality
US4290426A (en) * 1978-05-04 1981-09-22 Alza Corporation Dispenser for dispensing beneficial agent
US4434153A (en) * 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
US4721613A (en) * 1982-12-13 1988-01-26 Alza Corporation Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use
US4757128A (en) * 1986-08-01 1988-07-12 Massachusetts Institute Of Technology High molecular weight polyanhydride and preparation thereof
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4752470A (en) * 1986-11-24 1988-06-21 Mehta Atul M Controlled release indomethacin
US4853229A (en) * 1987-10-26 1989-08-01 Alza Corporation Method for adminstering tiny pills
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
US5180589A (en) * 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US4997904A (en) * 1989-08-25 1991-03-05 Nova Pharmaceutical Corporation Aromatic polyanhydride compositions
US5175235A (en) 1990-06-04 1992-12-29 Nova Pharmaceutical Corporation Branched polyanhydrides
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5286497A (en) 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5326570A (en) 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US6197346B1 (en) * 1992-04-24 2001-03-06 Brown Universtiy Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US6235313B1 (en) * 1992-04-24 2001-05-22 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US5256440A (en) 1992-06-22 1993-10-26 Merck & Co., Inc. Process for producing a tablet core aperture
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US5576311A (en) 1994-11-30 1996-11-19 Pharmos Corporation Cyclodextrins as suspending agents for pharmaceutical suspensions
NZ270078A (en) 1994-12-06 1998-05-27 Bernard Charles Sherman Diltiazem hydrochloride formulation comprising beads with immediate, intermediate, and delayed release dissolution profiles
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5998380A (en) 1995-10-13 1999-12-07 New England Medical Center Hospitals, Inc. Treatment of migraine
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6368586B1 (en) * 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
US5985312A (en) 1996-01-26 1999-11-16 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
KR100341829B1 (ko) * 1996-03-08 2002-08-22 니코메드 덴마크 에이/에스 방출특성이변형된다-유니트투여량조성물
US5955096A (en) 1996-06-25 1999-09-21 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
US5753693A (en) * 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US5760007A (en) * 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
US5935933A (en) * 1997-07-16 1999-08-10 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating neuropathic pain
US6066339A (en) 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
US20040028735A1 (en) * 1997-11-14 2004-02-12 Unchalee Kositprapa Pharmaceutical formulation
UA65607C2 (uk) * 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
US6524620B2 (en) * 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
CA2348871C (en) * 1998-11-02 2009-04-14 John G. Devane Multiparticulate modified release composition
EP1005863A1 (en) * 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
US6528090B2 (en) 1998-12-18 2003-03-04 Abbott Laboratories Controlled release formulation of divalproex sodium
US6797283B1 (en) * 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
ES2228465T3 (es) 1999-01-19 2005-04-16 Ortho-Mcneil Pharmaceutical, Inc. Uso derivados anticonvulsionantes para el tratamiento de cefaleas en brotes.
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
AU775849B2 (en) * 1999-04-08 2004-08-19 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in lowering blood pressure
US7056890B2 (en) * 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
IL148019A0 (en) 1999-08-20 2002-09-12 Ortho Mcneil Pharm Inc Composition comprising a tramadol material and an anticonvulsant drug
US6479467B1 (en) 1999-12-16 2002-11-12 Eastman Chemical Company Cyclodextrin ethers
SE0000601D0 (sv) * 2000-02-24 2000-02-24 Jan Hedner Sätt att behandla och diagnostisera andningsstörningar i sömnen och medel för att utföra sättet
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
DK1309324T3 (da) 2000-07-07 2006-06-12 Ortho Mcneil Pharm Inc Antikonvulsive derivater egnede til behandling og forebyggelse af udvikling af type II diabetes mellitus og syndrom X
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
US6344215B1 (en) 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
NZ537490A (en) * 2000-10-30 2006-11-30 Ortho Mcneil Pharm Inc Treatment of diabetes and syndrome X using a sulfamate derivate such as topiramate and metformin
WO2002043731A2 (en) 2000-11-30 2002-06-06 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing
TWI321054B (en) * 2000-12-19 2010-03-01 California Inst Of Techn Compositions containing inclusion complexes
AU2002320360B2 (en) * 2001-07-10 2005-05-26 Teva Pharmaceutical Industries Ltd. Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
US6500454B1 (en) 2001-10-04 2002-12-31 Eurand Pharmaceuticals Ltd. Timed, sustained release systems for propranolol
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US20030072802A1 (en) * 2001-10-11 2003-04-17 R.T. Alamo Ventures, Inc. Sustained release topiramate
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US7815936B2 (en) * 2001-10-30 2010-10-19 Evonik Degussa Gmbh Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
NZ552514A (en) 2001-12-24 2008-08-29 Teva Pharma Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
IL163720A0 (en) 2002-02-26 2005-12-18 Ortho Mcneil Pharm Inc Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents
CA2483827C (en) 2002-04-29 2012-01-24 Amir H. Shojaei Pharmaceutical formulations with improved bioavailability
AR039744A1 (es) * 2002-06-26 2005-03-09 Alza Corp Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
US20060088882A1 (en) 2002-06-27 2006-04-27 Jain Rakesh K Methods for the treatment or prevention of obesity
NZ537543A (en) * 2002-07-29 2007-08-31 Alza Corp Formulations and high dose osmotic dosage forms for controlled delivery of topiramate
US8268352B2 (en) * 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US8216609B2 (en) * 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
CN1688292A (zh) * 2002-09-04 2005-10-26 兰贝克赛实验室有限公司 掩味剂型及其制造方法
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
AU2002350719A1 (en) 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
AU2003296672A1 (en) 2002-12-13 2004-07-09 Cilag Ag Controlled release preparations comprising tramadol and topiramate
JP4469846B2 (ja) 2003-01-31 2010-06-02 エラン ファーマ インターナショナル,リミティド ナノ粒子状トピラメート製剤
US20040185097A1 (en) * 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US20060210633A1 (en) 2003-04-03 2006-09-21 Sun Pharmaceutical Industries Limited Programmed drug delivery system
CA2894736C (en) 2003-04-07 2019-07-16 Supernus Pharmaceuticals, Inc. Once daily formulations of tetracyclines
JP2007501248A (ja) * 2003-08-06 2007-01-25 アルザ・コーポレーシヨン 増進した分散調合物による長時間にわたるトピラメートの均一送達
US20050136108A1 (en) * 2003-08-22 2005-06-23 Yam Noymi V. Stepwise delivery of topiramate over prolonged period of time
WO2005020959A2 (en) * 2003-09-02 2005-03-10 Alza Corporation Novel drug compositions and dosage forms of topiramate
US7737133B2 (en) 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
US7611728B2 (en) * 2003-09-05 2009-11-03 Supernus Pharmaceuticals, Inc. Osmotic delivery of therapeutic compounds by solubility enhancement
WO2005030166A1 (en) 2003-09-26 2005-04-07 Alza Corporation Oros push-stick for controlled delivery of active agents
DK2210605T3 (en) 2003-11-04 2017-05-22 Tcd Royalty Sub Llc Daily single dose doses of trospium.
CN1901885A (zh) * 2003-11-13 2007-01-24 阿尔扎公司 包含低水溶性药物和环氧乙烷-环氧丙烷嵌段共聚物的熔混分散体
JP2007511519A (ja) * 2003-11-14 2007-05-10 アルザ・コーポレーシヨン 液状投薬形態物におけるトピラメートの制御放出
US7387793B2 (en) * 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
US7470435B2 (en) 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
US20050191343A1 (en) 2003-11-26 2005-09-01 Shire Laboratories, Inc. Micellar systems useful for delivery of lipophilic or hydrophobic compounds
WO2005063206A1 (en) * 2003-12-23 2005-07-14 Alza Corporation Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
MXPA06007510A (es) * 2003-12-29 2009-06-10 Johnson & Johnson Composiciones de farmaco y formas de dosis novedosas de topiramato.
ES2241478B1 (es) * 2004-02-13 2006-11-16 Lacer S.A. Preparacion farmaceutica para la liberacion sostenida de un principio farmaceuticamente activo.
EP1727538A2 (en) 2004-02-13 2006-12-06 Neuromolecular Inc. Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
US20050220596A1 (en) 2004-03-30 2005-10-06 Cnh America Llc Method and apparatus for hydraulically produced ground following of an unloading ramp for a cotton harvester
WO2006003403A1 (en) * 2004-07-02 2006-01-12 The University Court Of The University Of Edinburgh Fluid-bicontinuos particle-stabilised gels
JP2008507508A (ja) * 2004-07-22 2008-03-13 株式會社アモーレパシフィック トピラメート徐放性製剤及びその製造方法
KR101340946B1 (ko) * 2004-08-04 2013-12-13 알자 코포레이션 오름차 0차 방출 패턴을 나타내는 약물의 서방성 조성물,상기 조성물을 제조하는 방법
WO2006059237A1 (en) 2004-08-30 2006-06-08 Lunamed, Inc. 4-phenylbutyric acid controlled-release formulations for therapeutic use
US20060105045A1 (en) * 2004-11-08 2006-05-18 Buchanan Charles M Cyclodextrin solubilizers for liquid and semi-solid formulations
US20060121112A1 (en) * 2004-12-08 2006-06-08 Elan Corporation, Plc Topiramate pharmaceutical composition
GB2422149A (en) 2005-01-14 2006-07-19 Portela & Ca Sa Process for the preparation of 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide
US20060233892A1 (en) 2005-04-19 2006-10-19 Curt Hendrix Topiramate compositions for treatment of headache
US9161918B2 (en) * 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
US8491929B2 (en) 2005-06-23 2013-07-23 Vaunnex Inc. Bioadhesive polymers
US8784886B2 (en) 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
US8846100B2 (en) 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
US9744137B2 (en) * 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
DK2089005T3 (da) 2006-11-09 2010-07-19 Orexigen Therapeutics Inc Lagdelte farmaceutiske formuleringer omfattende et hurtigt opløsende mellemlag
EP2394643B1 (en) 2006-11-17 2015-09-02 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
CN102114002B (zh) * 2006-12-04 2016-05-11 苏佩努斯制药公司 托吡酯的增强的立即释放制剂

Similar Documents

Publication Publication Date Title
ES2312308T1 (es) Formulaciones de liberacion sostenida de topiramato.
CN101090718B (zh) 3-羟基-3-甲基戊二酰辅酶a还原酶抑制剂和抗高血压剂的复合剂型及其制备方法
EP3076951B1 (en) Process for the production of drug formulations for oral administration
JP2010511633A5 (enExample)
JP6356215B2 (ja) エベロリムスを含む医薬組成物
JP5911969B2 (ja) 心臓血管障害の治療方法
US20090263479A1 (en) Formulations for poorly permeable active pharmaceutical ingredients
JP2011516613A (ja) 好ましくはポサコナゾールおよびhpmcasを含む固体分散物中の経口用薬学的組成物
CN101528224A (zh) 包含坎地沙坦西酯的药用组合物
Nair et al. Poly (lactic acid-co-glycolic acid) Nanospheres improved the oral delivery of candesartan cilexetil
JP2016518398A (ja) 低用量医薬組成物
JP2017528497A5 (enExample)
AU2021414679A9 (en) Water-soluble cannabinoid formulation and preparation method therefor
JP2012516346A (ja) ピリドピリミジノンの経口用固体製剤
EP3572074B1 (en) Stabilized formulations of molindone
JP6666352B2 (ja) デュタステリド含有固体分散体及びこれを含む組成物
CN1946426B (zh) 用于口服施用HMG-CoA还原酶抑制剂的持续释放制剂和其制备方法
JP2006524190A5 (enExample)
CN108201535A (zh) 一种维利帕尼缓控释药物组合物及其用途
ES2663721T3 (es) Formulaciones de olmesartán
JP2009522258A (ja) 増大したバイオアベイラビリティを有するフェノフィブラートの医薬製剤
Verma et al. Loading and release of amphotericin-B from biodegradable poly (lactic-co-glycolic acid) nanoparticles
JP2010521494A (ja) 麻薬性および非麻薬性鎮痛剤の組み合わせ
CN116322657A (zh) 包括氘代丁苯那嗪的多颗粒剂型
WO2007064084A1 (en) Granules containing pranlukast and processes for the preparation thereof